E3 mRNA vaccine combined with antigen replicon RNA (BioNTech)

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameE3 mRNA vaccine combined with antigen replicon RNA (BioNTech)
Drug Alias NameN/A
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine
Mechanisms of ActionInterferon-induced, double-stranded RNA-activated protein kinase inhibitors
TargetsInterferon-induced, double-stranded RNA-activated protein kinase
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBiontech Rna Pharmaceuticals Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiontech Rna Pharmaceuticals Gmbh
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A